Diamyd nets $45 million up front from J&J for late-stage diabetes therapy
This article was originally published in Scrip
Executive Summary
Diamyd Medical of Sweden is to receive $45 million up front and potentially another $580 million in development and sales milestones following the signing of a development and commercialisation deal with J&J's Ortho-McNeil-Janssen Pharmaceuticals for its novel Diamyd diabetes therapy.